Literature DB >> 3926067

Failure of acyclovir cream in treatment of recurrent herpes labialis.

M Shaw, M King, J M Best, J E Banatvala, J R Gibson, M R Klaber.   

Abstract

A double blind, randomised, crossover placebo controlled trial of 5% acyclovir cream, applied topically five times a day for five days, was carried out in 45 patients with recurrent herpes labialis. These patients had a total of 72 episodes, 34 of which were treated with the 5% acyclovir cream and 38 with placebo cream. Treatment was begun by the patients as soon as possible after the onset of prodromal symptoms. There was no significant clinical benefit from treatment with acyclovir cream compared with placebo cream. The median healing times were nine days with acyclovir cream, 10 days with placebo cream, and 13 days when no treatment was given. The possibility that the 40% propylene glycol cream base alone has a therapeutic effect must therefore be considered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926067      PMCID: PMC1416195          DOI: 10.1136/bmj.291.6487.7

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  13 in total

1.  [Teaching of preventive medicine to the graduate in public health].

Authors:  B R Ordóñez
Journal:  Gac Med Mex       Date:  1975-05       Impact factor: 0.302

2.  The patient with recurrent aphthous ulcers and the patient with recurrent herpes labialis: a study of two population samples.

Authors:  I I Ship; V J Brightman; L L Laster
Journal:  J Am Dent Assoc       Date:  1967-09       Impact factor: 3.634

Review 3.  Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy.

Authors:  A P Fiddian; G R Kinghorn; D Goldmeier; E Rees; P Rodin; R N Thin; G A de Konig
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

Review 4.  Topical acyclovir therapy in patients with recurrent orofacial herpes simplex infections.

Authors:  W A Van Vloten; R N Swart; F Pot
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

5.  Sensitivity of herpes virus isolates from acyclovir clinical trials.

Authors:  P Collins; G Appleyard; N M Oliver
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

6.  Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents.

Authors:  J A Embil; R G Stephens; F R Manuel
Journal:  Can Med Assoc J       Date:  1975-10-04       Impact factor: 8.262

7.  Herpes virus in an obstetric hospital: I: Herpetic eruptions.

Authors:  L I Hatherley; K Hayes; E M Hennessy; I Jack
Journal:  Med J Aust       Date:  1980-08-23       Impact factor: 7.738

8.  Treatment of herpes labialis.

Authors:  A P Fiddian; J M Yeo; A E Clark
Journal:  J Infect       Date:  1983-05       Impact factor: 6.072

9.  Topical acyclovir in the management of recurrent herpes labialis.

Authors:  A P Fiddian; L Ivanyi
Journal:  Br J Dermatol       Date:  1983-09       Impact factor: 9.302

10.  Successful treatment of herpes labialis with topical acyclovir.

Authors:  A P Fiddian; J M Yeo; R Stubbings; D Dean
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-28
View more
  10 in total

Review 1.  Treatment and prevention of herpes labialis.

Authors:  Wim Opstelten; Arie Knuistingh Neven; Just Eekhof
Journal:  Can Fam Physician       Date:  2008-12       Impact factor: 3.275

Review 2.  Herpes labialis.

Authors:  Graham Worrall
Journal:  BMJ Clin Evid       Date:  2009-09-23

3.  Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.

Authors:  D I Bernstein; C J Schleupner; T G Evans; D A Blumberg; Y Bryson; K Grafford; P Broberg; S Martin-Munley; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Chemotherapy of herpesvirus infections: present successes and future hopes.

Authors:  S Crowe; J Mills
Journal:  Eur J Clin Microbiol       Date:  1985-10       Impact factor: 3.267

5.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Authors:  M N Ellis; D C Lobe; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.

Authors:  S E Barton; P E Munday; G R Kinghorn; W I van der Meijden; E Stolz; A Notowicz; S Rashid; J L Schuller; A J Essex-Cater; M H Kuijpers
Journal:  Genitourin Med       Date:  1986-08

8.  Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.

Authors:  Spotswood L Spruance; Robert Nett; Thomas Marbury; Ray Wolff; James Johnson; Theodore Spaulding
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 9.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 10.  A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections.

Authors:  S Leflore; P L Anderson; C V Fletcher
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.228

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.